Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The goal of this double-blind randomized, placebo-controlled cross-over trial is to evaluate
the effectiveness of GerenylGeranylAcetone (GGA) in patients with Heart Failure with a
preserved ejection fraction.
The main questions it aims to answer are:
- What is the effect of GGA on diastolic function?
- What is the effect of GGA on endothelial function?
Main study tasks:
- Participants will be treated with either GGA or placebo for 13 weeks. After this they
will have a break (wash-out) period for 6 weeks and then cross over to the other study
arm.
- Cardiac function will be measured using echocardiogram in all participants
- Renal measurements and endothelial measurements will be performed on the participants.
- Participants will perform a 5 minute walking distance test for functional capacity.
- Participants will fill out questionnaires to score signs & symptoms.
Researchers will compare the patients to themselves to see if the drug improves diastolic-
and endothelial function.